Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jon Glass

Showing results (21-30 of 37) with videos related to

Pageof 4
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 19, 2010
Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomasShannon E Fogh, David W Andrews, Jon Glass, et al.
Journal of Neuro-Oncology|March 25, 2020
Initial experience with scalp sparing radiation with concurrent temozolomide and tumor treatment fields (SPARE) for patients with newly diagnosed glioblastomaAndrew Song, Voichita Bar-Ad, Nina Martinez, et al.
American Journal of Clinical Oncology|April 12, 2019
Rapid Early Tumor Progression is Prognostic in Glioblastoma PatientsJoshua D Palmer, Deepak Bhamidipati, Gaurav Shukla, et al.
Journal of Neuro-Oncology|January 30, 2016
Phase I trial of panobinostat and fractionated stereotactic re-irradiation therapy for recurrent high grade gliomasWenyin Shi, Joshua D Palmer, Maria Werner-Wasik, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 30, 2016
Phase I and II Study of Induction Chemotherapy With Methotrexate, Rituximab, and Temozolomide, Followed By Whole-Brain Radiotherapy and Postirradiation Temozolomide for Primary CNS Lymphoma: NRG Oncology RTOG 0227Jon Glass, Minhee Won, Christopher J Schultz, et al.
Journal of Neuro-Oncology|December 14, 2017
Salvage fractionated stereotactic re-irradiation (FSRT) for patients with recurrent high grade gliomas progressed after bevacizumab treatmentWenyin Shi, Erik S Blomain, Joshua Siglin, et al.
International Journal of Radiation Oncology, Biology, Physics|June 13, 2012
A phase I study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomasRobert B Den, Mitchell Kamrava, Zhi Sheng, et al.
Journal of Neuro-Oncology|January 10, 2018
Correction to: Salvage fractionated stereotactic re-irradiation (FSRT) for patients with recurrent high grade gliomas progressed after bevacizumab treatmentWenyin Shi, Erik S Blomain, Joshua Siglin, et al.
Frontiers in Oncology|May 16, 2022
Scalp-Sparing Radiation With Concurrent Temozolomide and Tumor Treating Fields (SPARE) for Patients With Newly Diagnosed GlioblastomaRyan Miller, Andrew Song, Ayesha Ali, et al.
Journal of Neuro-Oncology|September 6, 2018
Bevacizumab and re-irradiation for recurrent high grade gliomas: does sequence matter?Joshua D Palmer, Deepak Bhamidipati, Andrew Song, et al.
Pageof 4

Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 19, 2010
Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomasShannon E Fogh, David W Andrews, Jon Glass, et al.
Journal of Neuro-Oncology|March 25, 2020
Initial experience with scalp sparing radiation with concurrent temozolomide and tumor treatment fields (SPARE) for patients with newly diagnosed glioblastomaAndrew Song, Voichita Bar-Ad, Nina Martinez, et al.
American Journal of Clinical Oncology|April 12, 2019
Rapid Early Tumor Progression is Prognostic in Glioblastoma PatientsJoshua D Palmer, Deepak Bhamidipati, Gaurav Shukla, et al.
Journal of Neuro-Oncology|January 30, 2016
Phase I trial of panobinostat and fractionated stereotactic re-irradiation therapy for recurrent high grade gliomasWenyin Shi, Joshua D Palmer, Maria Werner-Wasik, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 30, 2016
Phase I and II Study of Induction Chemotherapy With Methotrexate, Rituximab, and Temozolomide, Followed By Whole-Brain Radiotherapy and Postirradiation Temozolomide for Primary CNS Lymphoma: NRG Oncology RTOG 0227Jon Glass, Minhee Won, Christopher J Schultz, et al.
Journal of Neuro-Oncology|December 14, 2017
Salvage fractionated stereotactic re-irradiation (FSRT) for patients with recurrent high grade gliomas progressed after bevacizumab treatmentWenyin Shi, Erik S Blomain, Joshua Siglin, et al.
International Journal of Radiation Oncology, Biology, Physics|June 13, 2012
A phase I study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomasRobert B Den, Mitchell Kamrava, Zhi Sheng, et al.
Journal of Neuro-Oncology|January 10, 2018
Correction to: Salvage fractionated stereotactic re-irradiation (FSRT) for patients with recurrent high grade gliomas progressed after bevacizumab treatmentWenyin Shi, Erik S Blomain, Joshua Siglin, et al.
Frontiers in Oncology|May 16, 2022
Scalp-Sparing Radiation With Concurrent Temozolomide and Tumor Treating Fields (SPARE) for Patients With Newly Diagnosed GlioblastomaRyan Miller, Andrew Song, Ayesha Ali, et al.
Journal of Neuro-Oncology|September 6, 2018
Bevacizumab and re-irradiation for recurrent high grade gliomas: does sequence matter?Joshua D Palmer, Deepak Bhamidipati, Andrew Song, et al.
Pageof 4